Cyanotech Corporation

What they do

Cyanotech grows microalgae in open ponds on the Kona coast of Hawaii, relying on consistent sunlight, warm temperatures, and low rainfall. The company processes the algae into consumer-packaged goods sold through natural products distributors, retailers, and online channels, as well as bulk ingredients sold to manufacturers and formulators. Its primary products are Hawaiian Spirulina Pacifica and BioAstin Hawaiian Astaxanthin. Production is agricultural and capital-intensive, with a large fixed cost base that requires high volumes to absorb costs.

Revenue drivers

• Consumer-packaged goods — Sales of branded spirulina and astaxanthin products through natural products distributors, retailers, and online channels, primarily in the U.S. This is the higher-margin segment and a strategic focus.
• Bulk ingredient sales — Sales of spirulina and astaxanthin in bulk to manufacturers, formulators, and distributors worldwide for use in health foods, cosmetics, and dietary supplements.
• International sales — Generated 21% of revenues outside the U.S. in fiscal 2025, up from 18% in fiscal 2024. All sales are in U.S. currency, so there is no material foreign exchange exposure.

Recent performance

For the quarter ended September 30, 2025, revenue was $7.0 million, up from $5.8 million in the prior quarter and $6.2 million in the quarter ended December 31, 2024. Despite the sequential increase, the company reported a net loss of $3.2 million for fiscal year 2025, following a $5.3 million loss in fiscal 2024. Operating cash flow remained negative at -$1.2 million for fiscal 2025, though improved from -$455,000 in fiscal 2024. As of September 30, 2025, the company had $649,000 in cash and $1.0 million in long-term debt.

Strategy

Management aims to grow the market for its higher-margin consumer products by emphasizing the nutritional content of Hawaiian Spirulina Pacifica and the health benefits of BioAstin Hawaiian Astaxanthin. The company focuses on increasing production efficiencies in volume yield, potency, and quality to offset fixed production costs. It also seeks to maintain production volumes sufficient to absorb costs, despite weather and environmental variability. Recent 8-K filings indicate the company entered material agreements and took on direct financial obligations in 2025, though specifics are not detailed in the excerpts.

Risks

• Agricultural production variability — Weather and environmental factors, particularly during the winter growing season, can cause inconsistent production levels, leading to abnormal costs and inability to meet demand.
• Fixed cost structure — A large percentage of production costs are fixed, so production shortfalls result in underabsorbed overhead and reduced gross margins.
• Liquidity and financing — With $649,000 in cash and negative operating cash flow, the company may struggle to meet obligations or repay maturing indebtedness without additional financing.
• General economic conditions — Inflation, reduced consumer confidence, and economic downturns could decrease demand for dietary supplements and increase operating costs.

Outlook

Management does not provide specific financial guidance, but emphasizes efforts to increase production efficiencies and grow consumer product sales. The company faces ongoing risks related to weather variability, fixed costs, and liquidity. Recent material agreements and financial obligations may affect future operations, but details are not provided in the excerpts. Forward-looking statements highlight risks including volatility of crude oil prices, inflation, access to financing, and ability to generate sufficient revenues.